Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR029 in R/R B-cell NHL
NCT03344367Phase 1Unknown
- Sponsor
- Peking University
- Start
- Nov 2017
- Primary completion
- Oct 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relmacabtagene autoleucel in B-cell non-Hodgkin lymphoma, sponsored by Peking University. Primary endpoints: Treatment-related adverse events at 2 years, Dose-limiting toxicities at 28 days and 1 more. Status: unknown.
02
Drugs
relmacabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03344367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344367.